A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

BackgroundThere is a strong rational of using anti–programmed cell death protein-1 and its ligand (anti–PD-1/L1) antibodies in human papillomavirus (HPV)–induced cancers. However, anti–PD-1/L1 as monotherapy induces a limited number of objective responses. The development of novel combinations in or...

Full description

Bibliographic Details
Main Authors: Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, Marion Jacquin, Francois Ghiringhelli, Christelle de la Fouchardière, Benoit You, Tristan Maurina, Elsa Kalbacher, Fernando Bazan, Guillaume Meynard, Anne-Laure Clairet, Christine Fagnoni-Legat, Laurie Spehner, Adeline Bouard, Dewi Vernerey, Aurélia Meurisse, Stefano Kim, Christophe Borg, Laura Mansi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
HPV-related cancer
anal carcinoma
head and neck
cervix
atezolizumab
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.957580/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.957580/full

Similar Items